These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 14088966)
21. THE TREATMENT OF CARCINOMA IN DOGS' BLADDERS WITH CYTOTOXIC DRUGS. BOYLAND E; KINDER CH; WILLIAMS K Invest Urol; 1965 Mar; 2():446-52. PubMed ID: 14261785 [No Abstract] [Full Text] [Related]
22. [SPECTROPHOTOMETRIC DETERMINATION OF CYTOSTATICS FROM THE DICHLOROETHYLAMINE GROUP (DOPAN AND SARCOLYSIN) IN THE ULTRAVIOLET RANGE]. BLAZHEK IIa; KRACHMAR I Farm Zh; 1965; 20():22-5. PubMed ID: 14348007 [No Abstract] [Full Text] [Related]
23. SOME OBSERVATIONS ON THE REACTIONS OF CHLORAMBUCIL, AZO-MUSTARD (CB 1414), AND CYCLOPHOSPHAMIDE. ISRAELS LG; LINFORD JH Proc Can Cancer Conf; 1963; 5():399-415. PubMed ID: 14278870 [No Abstract] [Full Text] [Related]
24. QUALITATIVE AND QUANTITATIVE TESTS FOR URACIL MUSTARD. SVOBODA GH; BARNES AJ J Pharm Sci; 1964 Oct; 53():1232-4. PubMed ID: 14249446 [No Abstract] [Full Text] [Related]
25. THE DURATION OF THE MYELOTOXIC EFFECTS OF CIRCULATING ALKYLATING AGENTS. ULFOHN A; KRAMER SP; DORFMAN H; WITTEN B; WILLIAMSON C; SASS S; MILLER JI; SELIGMAN AM Cancer Res; 1964 Oct; 24():1659-65. PubMed ID: 14234010 [No Abstract] [Full Text] [Related]
26. GROWTH INHIBITION OF A SPECTRUM OF TRANSPLANTED MOUSE TUMORS BY COMBINATIONS OF INHIBITORS OF NUCLEIC ACID BIOSYNTHESIS AND ALKYLATING AGENTS. BOOTH BA; SARTORELLI AC Cancer Res; 1963 Dec; 23():1762-8. PubMed ID: 14082870 [No Abstract] [Full Text] [Related]
27. 2-Fluoroethylamines. 3. Some alkylating agents derived from uracil. Martinez AP; Lee WW; Goodman L J Med Chem; 1968 Mar; 11(2):384-7. PubMed ID: 5663637 [No Abstract] [Full Text] [Related]
28. A comparison of the biological activity of uracil mustard and Dopan. PETERING HG; BUSKIRK HH; MUSSER EA; EVANS JS Cancer Chemother Rep; 1963 Mar; 27():1-10. PubMed ID: 13942713 [No Abstract] [Full Text] [Related]
30. Uracil mustard, a new alkylating agent for oral administration in the management of patients with leukemia and lymphoma. KENNEDY BJ; THEOLOGIDES A N Engl J Med; 1961 Apr; 264():790-3. PubMed ID: 13752496 [No Abstract] [Full Text] [Related]
31. Modulation of the toxicity and antitumour activity of alkylating drugs by steroids. Shepherd R; Harrap KR Br J Cancer; 1982 Mar; 45(3):413-20. PubMed ID: 7073935 [TBL] [Abstract][Full Text] [Related]
32. [STUDIES ON SYNTHETIC SWEETENING AGENTS. V. COLORIMETRIC DETERMINATION OF DULCIN]. ICHIBAGASE H; KOJIMA S; ICHIKAWA M Yakugaku Zasshi; 1964 Aug; 84():707-10. PubMed ID: 14236233 [No Abstract] [Full Text] [Related]
33. USE OF CATIONS FOR THE QUANTITATIVE DETERMINATION OF SOME NEW DRUGS. IAMPOLSKA MM Farm Zh; 1963; 18():8-12. PubMed ID: 14132326 [No Abstract] [Full Text] [Related]
34. Membrane transport of alkylating agents. Goldenberg GJ; Begleiter A Pharmacol Ther; 1980; 8(2):237-74. PubMed ID: 6992155 [No Abstract] [Full Text] [Related]
35. EFFECTS OF URACIL MUSTARD ON IN VIVO INCORPORATION OF PRECURSORS INTO NUCLEIC ACIDS OF THE WALKER TUMOR. SMITH SJ; BUSCH H Tex Rep Biol Med; 1964; 22():731-40. PubMed ID: 14226996 [No Abstract] [Full Text] [Related]
36. CYTO-ACTIVE AMINO-ACIDS AND PEPTIDES. XI. NITROGEN MUSTARD DERIVATIVES OF GLUTAMIC ACID AND RELATED COMPOUNDS. SZEKERKE M; WADE R; BERGEL F J Chem Soc; 1965 Mar; ():1907-12. PubMed ID: 14288325 [No Abstract] [Full Text] [Related]
37. EFFECTS OF URACIL MUSTARD ON INCORPORATION OF L-LYSINE-U-14C INTO ACIDIC NUCLEOLAR PROTEINS OF THE WALKER TUMOR AND LIVER. DESJARDINS R; BUSCH H Tex Rep Biol Med; 1964; 22():444-53. PubMed ID: 14221508 [No Abstract] [Full Text] [Related]
38. [USE OF DIMEZOL-14 IN PROTECTING ACT. AUREOFACIENS MYCELIA FROM THE ACTION OF TYPE I ACTINOPHAGE]. GOLDFARB DM; BORISOVA LN Antibiotiki; 1963 Dec; 8():1071-4. PubMed ID: 14172760 [No Abstract] [Full Text] [Related]